Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMD2GKF)

Drug Name

SFLT-01 Drug Info

Synonyms

AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme

Indication

Disease Entry	ICD 11	Status	REF
Macular degeneration	9B78.3	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DMD2GKF

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Placenta growth factor (PlGF)	TT48I1Y	PLGF_HUMAN	Modulator	[2]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Vascular endothelial growth factor A (VEGFA)	DTT	VEGFA	8.544	6.927	7.253	7.839
Placenta growth factor (PlGF)	DTT	PGF	6.163	7.095	7.039	7.016

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Macular degeneration

ICD Disease Classification

9B78.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Vascular endothelial growth factor A (VEGFA)	DTT	VEGFA	3.61E-01	0.15	0.47

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01024998) Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD). U.S. National Institutes of Health.
2	sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.